Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-miR-27a
- Development stage
- Preclinical
- Lead developer
- Khulna University
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
anti-miR-27a is an antisense oligonucleotide (antagomir) designed to specifically bind and inhibit the activity of microRNA-27a (miR-27a). In oncological research, particularly epithelial ovarian cancer, miR-27a has been identified as a regulator of heparin-binding EGF-like growth factor (HB-EGF) by binding to its 3'UTR. While miR-27a often acts as a tumor suppressor in this context, anti-miR-27a is utilized in loss-of-function studies to demonstrate the reciprocal relationship between the miRNA and its target mRNA/protein. Experimental use of anti-miR-27a has shown it can upregulate endogenous hHB-EGF expression, providing insights into the miRNA-mediated deregulation pathways in human carcinogenesis.
- Other names
- miR-27a inhibitormiR27a inhibitormiR 27a inhibitorantagomir-27aantagomir27aantagomir 27aanti-microRNA-27aanti-microRNA27aanti-microRNA 27a
Beyond the preview
Go deeper on anti-miR-27a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-miR-27a.